Global Anti Vascular Endothelial Growth Factor Therapeutics Market Report 2024

Anti-Vascular Endothelial Growth Factor Therapeutics Global Market Report 2024 – By Product (Eylea, Lucentis, Beovu), By Disease (Macular Edema, Diabetic Retinopathy, Retinal Vein Occlusion, Age-related Macular Degeneration), By End Users (Hospitals, Clinics, Oncology Centers, Other End Users) – Market Size, Trends, And Global Forecast 2024-2033

Starting Price : $5000.00 | Pages : | Published : January 2024 | Delivery Time: 2-3 business days | Format : pdf

Need assistance or more information before the purchase?

Enquire Before Buying
Anti-Vascular Endothelial Growth Factor Therapeutics Global Market Report 2023

Proud Members Of

checkslacipN checkaoirsN checkscipN

Anti-Vascular Endothelial Growth Factor Therapeutics Market Definition And Segments

Anti-Vascular Endothelial Growth Factor (VEGF) therapeutics are drugs that inhibit the growth of blood vessels, commonly used in the treatment of ophthalmic diseases. These drugs inhibit vascular endothelial growth factors. It is utilized in the therapy of some tumors and in treating age-related macular degeneration.

The main products of anti-vascular endothelial growth factor therapeutics are Eylea, Lucentis, and Beovu. Eylea refers to a medication used to treat certain eye conditions, including macular degeneration and diabetic retinopathy. It is used as an anti-vascular endothelial growth factor (anti-VEGF) therapeutic agent to inhibit abnormal blood vessel growth in the eye, often associated with retinal diseases. The anti-vascular endothelial growth factor therapeutics are used for treating macular edema, diabetic retinopathy, retinal vein occlusion, and age-related macular degeneration by hospitals, clinics, oncology centers, and others.

The anti-vascular endothelial growth factor therapeutics market covered in this report is segmented –

1) By Product: Eylea, Lucentis, Beovu

2) By Disease: Macular Edema, Diabetic Retinopathy, Retinal Vein Occlusion, Age-related Macular Degeneration

3) By End Users: Hospitals, Clinics, Oncology Centers, Other End Users

The anti-vascular endothelial growth factor therapeutics market size has grown marginally in recent years. It will grow from $12.18 billion in 2023 to $12.35 billion in 2024 at a compound annual growth rate (CAGR) of 1.3%. The growth in the historic period can be attributed to rise in age-related macular degeneration, increased incidence of diabetic retinopathy, advancements in retinal disease diagnosis, clinical success and efficacy, shift to outpatient treatment.

The anti-vascular endothelial growth factor therapeutics market size is expected to see marginal growth in the next few years. It will grow to $13.13 billion in 2028 at a compound annual growth rate (CAGR) of 1.5%. The growth in the forecast period can be attributed to aging population and ocular diseases, expanding applications in retinal disorders, development of next-generation therapeutics, increasing emphasis on early intervention, global health initiatives and access to treatment. Major trends in the forecast period include increasing utilization in cancer treatment, focus on combination therapies in ophthalmology, exploration of biosimilar versions, research on resistance mechanisms, integration with imaging technologies.

Rising Prevalence Of Ophthalmic Diseases Drives Growth In The Anti-VEGF Therapeutics Market

The increase in the prevalence of ophthalmic diseases is expected to propel the growth of the anti-vascular endothelial growth factor therapeutics market going forward. The prevalence of ophthalmic diseases refers to the number or proportion of individuals within a given population who have been diagnosed with or exhibit specific eye conditions or diseases. Anti-vascular endothelial growth factor (VEGF) therapeutics help reduce the prevalence of ophthalmic diseases by effectively treating ailments such as wet age-related macular degeneration (AMD), diabetic retinopathy, and retinal vein occlusion. For instance, in October 2022, according to World Health Organization, a Switzerland-based international public health organization, globally, around 2.2 billion people have near or distance vision impairment, and 1 billion people suffer from near or distance vision impairment. Further, among these, 88.4 million are suffering from refractive error, 94 million have cataracts, 8 million have age-related macular degeneration, and around 3.9 million have diabetic retinopathy. Therefore, the increase in the prevalence of ophthalmic diseases is driving the growth of the anti-vascular endothelial growth factor therapeutics market.

Increasing Healthcare Infrastructure Expenditure Boosts Growth In The Anti-VEGF Therapeutics Market

Growing expenditure on healthcare infrastructure is expected to propel the growth of the anti-vascular endothelial growth factor therapeutics market going forward. Healthcare infrastructure expenditure refers to the financial resources allocated to the development, maintenance, and improvement of healthcare facilities and related assets, such as hospitals, clinics, medical equipment, and information systems. Healthcare infrastructure expenditure plays a crucial role in the anti-VEGF therapeutics market by improving access to treatment, supporting the adoption of new technologies, increasing awareness and early detection, and fostering public-private collaboration in research and development. For instance, in May 2023, according to a report published by the Office for National Statistics, a UK-based government department, between 2020 and 2021, healthcare spending in the UK increased by 9.4% in nominal terms and 9.7% in real terms. Furthermore, spending on preventive care was $45.72 billion in 2021, more than doubling from 2020. Therefore, growing expenditure on healthcare infrastructure is driving the growth of the anti-vascular endothelial growth factor therapeutics market.

Major companies operating in the anti-vascular endothelial growth factor therapeutics market report are F. Hoffmann-La Roche AG, Biogen Inc., Pfizer Inc., Coherus BioSciences Inc., Applied Molecular Genetics Inc., Eli Lilly and Company, Bausch Health Companies Inc., Viatris Inc., Xbrane Biopharma AB, Bayer AG, Regeneron Pharmaceuticals Inc., Genentech Inc., Allergan Inc., Novartis AG, kyowa Kirin Co. Ltd., Amgen Inc., AstraZeneca PLC, Merck & Co. Inc., Johnson & Johnson Private Limited, Sanofi S.A., AbbVie Inc., Takeda Pharmaceutical Company Limited, Astellas Pharma Inc., Bristol-Myers Squibb Company, Boehringer Ingelheim International GmbH, Daiichi Sankyo Company Limited, Eisai Co. Ltd., Gilead Sciences Inc., Vertex Pharmaceuticals Incorporated, Alexion Pharmaceuticals Inc.

Advancements In Therapeutics Drive Growth In The Anti-Vegf Therapeutics Market

Advancements in therapeutics are a key trend gaining popularity in the anti-vascular endothelial growth factor therapeutics market. Companies operating in the anti-vascular endothelial growth factor therapeutics market are adopting advanced therapeutics to sustain their position in the market. For instance, in May 2022, Ashvattha Therapeutics Inc., a US-based clinical-stage biopharmaceutical company, released phase 1 safety data for healthy subjects for subcutaneous anti-VEGF wet AMD (age-related macular degeneration) and DME (diabetic macular edema) candidates. D-4517.2 therapy is a first-in-class therapy developed to address the unmet needs of DME conditions. D-4517.2 therapy is being developed for self-administration using an autoinjector. The autoinjector D-4517.2 enable patients to self-administer the medication once a month in the comfort of their home.

Strategic Partnerships Drive Commercialization Efforts In The Anti-Vegf Therapeutics Market

Major companies operating in the anti-vascular endothelial growth factor therapeutics market are integrating their efforts in adopting strategic partnerships to develop and commercialize VEGF inhibitors and maximize their profits in the market. Such collaborations are essential for driving research and development, accessing new technologies and candidates, expanding market reach, and supporting the commercialization of VEGF inhibitors. For instance, in June 2022, Biogen Inc., a US-based biotechnology company, in partnership with Samsung Bioepis, a South Korea-based biopharmaceutical company, launched BYOOVIZ (ranibizumab-nuna) in the United States. BYOOVIZ, the first FDA-approved ophthalmology biosimilar, is indicated for the treatment of neovascular (wet) age-related macular degeneration (AMD), macular edema following retinal vein occlusion, and myopic choroidal neovascularization. It is a vascular endothelial growth factor (VEGF) inhibitor and the first biosimilar launch in the U.S. under the Biogen and Samsung Bioepis’ partnership, where Samsung Bioepis is responsible for the development, regulatory registration, and manufacture of the products, while Biogen is responsible for commercialization.

AbbVie Inc. And Regenxbio Inc. Collaborate For Anti-Vegf Eye Gene Therapy Development

In September 2021, AbbVie Inc., a US-based pharmaceutical and medicine innovator company, entered into a partnership agreement with Regenxbio Inc. for $370 million. This partnership will combine eye care and gene therapy expertise to develop anti-VEGF eye gene therapy. This developmental study uses RGX-314 gene therapy which inhibits VEGF and is designed for treating wet age-related macular degeneration (AMD), retinal diseases, and diabetic retinopathy. Regenxbio Inc is a US-based biotechnology company focused on developing recombinant gene therapies.

North America was the largest region in the anti-vascular endothelial growth factor therapeutics market in 2023. Europe is expected to be the fastest-growing region in the global anti-vascular endothelial growth factor therapeutics market report during the forecast period. The regions covered in the anti-vascular endothelial growth factor therapeutics market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa

The countries covered in the anti-vascular endothelial growth factor therapeutics market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain

The anti-vascular endothelial growth factor therapeutics market consists of revenues earned by entities by providing lapatinib (tykerb), sorafenib (nexavar), sunitinib (sutent), axitinib, and pazopanib. The market value includes the value of related goods sold by the service provider or included within the service offering. The anti-vascular endothelial growth factor therapeutics market also includes sales of drugs, injectables, and therapy-related products. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

The anti-vascular endothelial growth factor therapeutics market research report is one of a series of new reports from The Business Research Company that provides anti-vascular endothelial growth factor therapeutics market statistics, including anti-vascular endothelial growth factor therapeutics industry global market size, regional shares, competitors with an anti-vascular endothelial growth factor therapeutics market share, detailed anti-vascular endothelial growth factor therapeutics market segments, market trends, and opportunities, and any further data you may need to thrive in the anti-vascular endothelial growth factor therapeutics industry. This anti-vascular endothelial growth factor therapeutics market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

Anti-Vascular Endothelial Growth Factor Therapeutics Market Report Scope
Report AttributeDetails
Market Size Value In 2024 $12.35 billion
Revenue Forecast In 2033 $13.13 billion
Growth Rate CAGR of 1.5% from 2024 to 2033
Base Year For Estimation 2023
Actual Estimates/Historical Data 2018-2023
Forecast Period 2024 - 2028 - 2033
Market Representation Revenue in USD Billion and CAGR from 2024 to 2033
Segments Covered 1) By Product: Eylea, Lucentis, Beovu
2) By Disease: Macular Edema, Diabetic Retinopathy, Retinal Vein Occlusion, Age-related Macular Degeneration
3) By End Users: Hospitals, Clinics, Oncology Centers, Other End Users
Regional Scope Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
Country Scope Australia; China; India; Indonesia; Japan; South Korea; Bangladesh; Thailand; Vietnam; Malaysia; Singapore; Philippines; Hong Kong; New Zealand; USA; Canada; Mexico; Brazil; Chile; Argentina; Colombia; Peru; France; Germany; UK; Austria; Belgium; Denmark; Finland; Ireland; Italy; Netherlands; Norway; Portugal; Spain; Sweden; Switzerland; Russia; Czech Republic; Poland; Romania; Ukraine; Saudi Arabia; Israel; Iran; Turkey; UAE; Egypt; Nigeria; South Africa
Key Companies Profiled F. Hoffmann-La Roche AG; Biogen Inc.; Pfizer Inc.; Coherus BioSciences Inc.; Applied Molecular Genetics Inc.; Eli Lilly and Company; Bausch Health Companies Inc.; Viatris Inc.; Xbrane Biopharma AB; Bayer AG; Regeneron Pharmaceuticals Inc.; Genentech Inc; Allergan Inc.; Novartis AG; kyowa Kirin Co. Ltd.; Amgen Inc.; AstraZeneca plc; Merck & Co. Inc.; Johnson & Johnson Private Limited; Sanofi S.A.; AbbVie Inc.; Takeda Pharmaceutical Company Limited; Astellas Pharma Inc.; Bristol-Myers Squibb Company; Boehringer Ingelheim International GmbH; Daiichi Sankyo Company Limited; Eisai Co. Ltd.; Gilead Sciences Inc.; Vertex Pharmaceuticals Incorporated; Alexion Pharmaceuticals Inc.
Customization ScopeRequest for Sample
Pricing And Purchase OptionsExplore Purchase Options

    Table Of Contents

    1. Executive Summary

    2. Anti-Vascular Endothelial Market Characteristics

    3. Anti-Vascular Endothelial Market Trends And Strategies

    4. Anti-Vascular Endothelial Market - Macro Economic Scenario

    4.1. Impact Of High Inflation On the Market

    4.2. Ukraine-Russia War Impact On the Market

    4.3. COVID-19 Impact On the Market

    5. Global Anti-Vascular Endothelial Market Size and Growth

    5.1. Global Anti-Vascular Endothelial Market Drivers and Restraints

    5.1.1. Drivers Of The Market

    5.1.2. Restraints Of The Market

    5.2. Global Anti-Vascular Endothelial Historic Market Size and Growth, 2018 - 2023, Value ($ Billion)

    5.3. Global Anti-Vascular Endothelial Forecast Market Size and Growth, 2023 - 2028, 2033F, Value ($ Billion)

    6. Anti-Vascular Endothelial Market Segmentation

    6.1. Global Anti-Vascular Endothelial Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    Eylea

    Lucentis

    Beovu

    6.2. Global Anti-Vascular Endothelial Market, Segmentation By Disease, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    Macular Edema

    Diabetic Retinopathy

    Retinal Vein Occlusion

    Age-related Macular Degeneration

    6.3. Global Anti-Vascular Endothelial Market, Segmentation By End-Users, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    Hospitals

    Clinics

    Oncology Centers

    Other End Users

    7. Anti-Vascular Endothelial Market Regional And Country Analysis

    7.1. Global Anti-Vascular Endothelial Market, Split By Region, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    7.2. Global Anti-Vascular Endothelial Market, Split By Country, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    8. Asia-Pacific Anti-Vascular Endothelial Market

    8.1. Asia-Pacific Anti-Vascular Endothelial Market Overview

    Region Information, Impact Of COVID-19, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies

    8.2. Asia-Pacific Anti-Vascular Endothelial Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    8.3. Asia-Pacific Anti-Vascular Endothelial Market, Segmentation By Disease, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    8.4. Asia-Pacific Anti-Vascular Endothelial Market, Segmentation By End-Users, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    9. China Anti-Vascular Endothelial Market

    9.1. China Anti-Vascular Endothelial Market Overview

    9.2. China Anti-Vascular Endothelial Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F,$ Billion

    9.3. China Anti-Vascular Endothelial Market, Segmentation By Disease, Historic and Forecast, 2018-2023, 2023-2028F, 2033F,$ Billion

    9.4. China Anti-Vascular Endothelial Market, Segmentation By End-Users, Historic and Forecast, 2018-2023, 2023-2028F, 2033F,$ Billion

    10. India Anti-Vascular Endothelial Market

    10.1. India Anti-Vascular Endothelial Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    10.2. India Anti-Vascular Endothelial Market, Segmentation By Disease, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    10.3. India Anti-Vascular Endothelial Market, Segmentation By End-Users, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    11. Japan Anti-Vascular Endothelial Market

    11.1. Japan Anti-Vascular Endothelial Market Overview

    11.2. Japan Anti-Vascular Endothelial Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    11.3. Japan Anti-Vascular Endothelial Market, Segmentation By Disease, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    11.4. Japan Anti-Vascular Endothelial Market, Segmentation By End-Users, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    12. Australia Anti-Vascular Endothelial Market

    12.1. Australia Anti-Vascular Endothelial Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    12.2. Australia Anti-Vascular Endothelial Market, Segmentation By Disease, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    12.3. Australia Anti-Vascular Endothelial Market, Segmentation By End-Users, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    13. Indonesia Anti-Vascular Endothelial Market

    13.1. Indonesia Anti-Vascular Endothelial Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    13.2. Indonesia Anti-Vascular Endothelial Market, Segmentation By Disease, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    13.3. Indonesia Anti-Vascular Endothelial Market, Segmentation By End-Users, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    14. South Korea Anti-Vascular Endothelial Market

    14.1. South Korea Anti-Vascular Endothelial Market Overview

    14.2. South Korea Anti-Vascular Endothelial Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    14.3. South Korea Anti-Vascular Endothelial Market, Segmentation By Disease, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    14.4. South Korea Anti-Vascular Endothelial Market, Segmentation By End-Users, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    15. Western Europe Anti-Vascular Endothelial Market

    15.1. Western Europe Anti-Vascular Endothelial Market Overview

    15.2. Western Europe Anti-Vascular Endothelial Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    15.3. Western Europe Anti-Vascular Endothelial Market, Segmentation By Disease, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    15.4. Western Europe Anti-Vascular Endothelial Market, Segmentation By End-Users, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    16. UK Anti-Vascular Endothelial Market

    16.1. UK Anti-Vascular Endothelial Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    16.2. UK Anti-Vascular Endothelial Market, Segmentation By Disease, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    16.3. UK Anti-Vascular Endothelial Market, Segmentation By End-Users, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    17. Germany Anti-Vascular Endothelial Market

    17.1. Germany Anti-Vascular Endothelial Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    17.2. Germany Anti-Vascular Endothelial Market, Segmentation By Disease, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    17.3. Germany Anti-Vascular Endothelial Market, Segmentation By End-Users, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    18. France Anti-Vascular Endothelial Market

    18.5. France Anti-Vascular Endothelial Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    18.6. France Anti-Vascular Endothelial Market, Segmentation By Disease, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    18.7. France Anti-Vascular Endothelial Market, Segmentation By End-Users, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    19. Italy Anti-Vascular Endothelial Market

    19.9. Italy Anti-Vascular Endothelial Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    19.10. Italy Anti-Vascular Endothelial Market, Segmentation By Disease, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    19.11. Italy Anti-Vascular Endothelial Market, Segmentation By End-Users, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    20. Spain Anti-Vascular Endothelial Market

    20.13. Spain Anti-Vascular Endothelial Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    20.14. Spain Anti-Vascular Endothelial Market, Segmentation By Disease, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    20.15. Spain Anti-Vascular Endothelial Market, Segmentation By End-Users, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    21. Eastern Europe Anti-Vascular Endothelial Market

    21.1. Eastern Europe Anti-Vascular Endothelial Market Overview

    21.2. Eastern Europe Anti-Vascular Endothelial Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    21.3. Eastern Europe Anti-Vascular Endothelial Market, Segmentation By Disease, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    21.4. Eastern Europe Anti-Vascular Endothelial Market, Segmentation By End-Users, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    22. Russia Anti-Vascular Endothelial Market

    22.1. Russia Anti-Vascular Endothelial Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    22.2. Russia Anti-Vascular Endothelial Market, Segmentation By Disease, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    22.3. Russia Anti-Vascular Endothelial Market, Segmentation By End-Users, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    23. North America Anti-Vascular Endothelial Market

    23.1. North America Anti-Vascular Endothelial Market Overview

    23.2. North America Anti-Vascular Endothelial Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    23.3. North America Anti-Vascular Endothelial Market, Segmentation By Disease, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    23.4. North America Anti-Vascular Endothelial Market, Segmentation By End-Users, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    24. USA Anti-Vascular Endothelial Market

    24.1. USA Anti-Vascular Endothelial Market Overview

    24.2. USA Anti-Vascular Endothelial Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    24.3. USA Anti-Vascular Endothelial Market, Segmentation By Disease, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    24.4. USA Anti-Vascular Endothelial Market, Segmentation By End-Users, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    25. Canada Anti-Vascular Endothelial Market

    25.1. Canada Anti-Vascular Endothelial Market Overview

    25.2. Canada Anti-Vascular Endothelial Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    25.3. Canada Anti-Vascular Endothelial Market, Segmentation By Disease, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    25.4. Canada Anti-Vascular Endothelial Market, Segmentation By End-Users, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    26. South America Anti-Vascular Endothelial Market

    26.1. South America Anti-Vascular Endothelial Market Overview

    26.2. South America Anti-Vascular Endothelial Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    26.3. South America Anti-Vascular Endothelial Market, Segmentation By Disease, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    26.4. South America Anti-Vascular Endothelial Market, Segmentation By End-Users, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    27. Brazil Anti-Vascular Endothelial Market

    27.1. Brazil Anti-Vascular Endothelial Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    27.2. Brazil Anti-Vascular Endothelial Market, Segmentation By Disease, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    27.3. Brazil Anti-Vascular Endothelial Market, Segmentation By End-Users, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    28. Middle East Anti-Vascular Endothelial Market

    28.1. Middle East Anti-Vascular Endothelial Market Overview

    28.2. Middle East Anti-Vascular Endothelial Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    28.3. Middle East Anti-Vascular Endothelial Market, Segmentation By Disease, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    28.4. Middle East Anti-Vascular Endothelial Market, Segmentation By End-Users, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    29. Africa Anti-Vascular Endothelial Market

    29.1. Africa Anti-Vascular Endothelial Market Overview

    29.2. Africa Anti-Vascular Endothelial Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    29.3. Africa Anti-Vascular Endothelial Market, Segmentation By Disease, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    29.4. Africa Anti-Vascular Endothelial Market, Segmentation By End-Users, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    30. Anti-Vascular Endothelial Market Competitive Landscape And Company Profiles

    30.1. Anti-Vascular Endothelial Market Competitive Landscape

    30.2. Anti-Vascular Endothelial Market Company Profiles

    30.2.1. F. Hoffmann-La Roche AG

    30.2.1.1. Overview

    30.2.1.2. Products and Services

    30.2.1.3. Strategy

    30.2.1.4. Financial Performance

    30.2.2. Biogen Inc.

    30.2.2.1. Overview

    30.2.2.2. Products and Services

    30.2.2.3. Strategy

    30.2.2.4. Financial Performance

    30.2.3. Pfizer Inc.

    30.2.3.1. Overview

    30.2.3.2. Products and Services

    30.2.3.3. Strategy

    30.2.3.4. Financial Performance

    30.2.4. Coherus BioSciences Inc.

    30.2.4.1. Overview

    30.2.4.2. Products and Services

    30.2.4.3. Strategy

    30.2.4.4. Financial Performance

    30.2.5. Applied Molecular Genetics Inc.

    30.2.5.1. Overview

    30.2.5.2. Products and Services

    30.2.5.3. Strategy

    30.2.5.4. Financial Performance

    31. Global Anti-Vascular Endothelial Market Competitive Benchmarking

    32. Global Anti-Vascular Endothelial Market Competitive Dashboard

    33. Key Mergers And Acquisitions In The Anti-Vascular Endothelial Market

    34. Anti-Vascular Endothelial Market Future Outlook and Potential Analysis

    34.1 Anti-Vascular Endothelial Market In 2028 - Countries Offering Most New Opportunities

    34.2 Anti-Vascular Endothelial Market In 2028 - Segments Offering Most New Opportunities

    34.3 Anti-Vascular Endothelial Market In 2028 - Growth Strategies

    34.3.1 Market Trend Based Strategies

    34.3.2 Competitor Strategies

    35. Appendix

    35.1. Abbreviations

    35.2. Currencies

    35.3. Historic And Forecast Inflation Rates

    35.4. Research Inquiries

    35.5. The Business Research Company

    35.6. Copyright And Disclaimer

List Of Tables

    Table 1: Global Historic Market Growth, 2018-2023, $ Billion
  • Table 2: Global Forecast Market Growth, 2023-2028F, 2033F, $ Billion
  • Table 3: Global Anti-Vascular Endothelial Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 4: Global Anti-Vascular Endothelial Market, Segmentation By Disease, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 5: Global Anti-Vascular Endothelial Market, Segmentation By End-Users, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 6: Global Anti-Vascular Endothelial Market, Split By Region, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 7: Global Anti-Vascular Endothelial Market, Split By Country, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 8: Asia-Pacific, Anti-Vascular Endothelial Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 9: Asia-Pacific, Anti-Vascular Endothelial Market, Segmentation By Disease, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 10: Asia-Pacific, Anti-Vascular Endothelial Market, Segmentation By End-Users, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 11: China, Anti-Vascular Endothelial Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 12: China, Anti-Vascular Endothelial Market, Segmentation By Disease, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 13: China, Anti-Vascular Endothelial Market, Segmentation By End-Users, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 14: India, Anti-Vascular Endothelial Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 15: India, Anti-Vascular Endothelial Market, Segmentation By Disease, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 16: India, Anti-Vascular Endothelial Market, Segmentation By End-Users, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 17: Japan, Anti-Vascular Endothelial Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 18: Japan, Anti-Vascular Endothelial Market, Segmentation By Disease, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 19: Japan, Anti-Vascular Endothelial Market, Segmentation By End-Users, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 20: Australia, Anti-Vascular Endothelial Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 21: Australia, Anti-Vascular Endothelial Market, Segmentation By Disease, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 22: Australia, Anti-Vascular Endothelial Market, Segmentation By End-Users, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 23: Indonesia, Anti-Vascular Endothelial Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 24: Indonesia, Anti-Vascular Endothelial Market, Segmentation By Disease, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 25: Indonesia, Anti-Vascular Endothelial Market, Segmentation By End-Users, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 26: South Korea, Anti-Vascular Endothelial Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 27: South Korea, Anti-Vascular Endothelial Market, Segmentation By Disease, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 28: South Korea, Anti-Vascular Endothelial Market, Segmentation By End-Users, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 29: Western Europe, Anti-Vascular Endothelial Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 30: Western Europe, Anti-Vascular Endothelial Market, Segmentation By Disease, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 31: Western Europe, Anti-Vascular Endothelial Market, Segmentation By End-Users, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 32: UK, Anti-Vascular Endothelial Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 33: UK, Anti-Vascular Endothelial Market, Segmentation By Disease, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 34: UK, Anti-Vascular Endothelial Market, Segmentation By End-Users, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 35: Germany, Anti-Vascular Endothelial Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 36: Germany, Anti-Vascular Endothelial Market, Segmentation By Disease, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 37: Germany, Anti-Vascular Endothelial Market, Segmentation By End-Users, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 38: France, Anti-Vascular Endothelial Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 39: France, Anti-Vascular Endothelial Market, Segmentation By Disease, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 40: France, Anti-Vascular Endothelial Market, Segmentation By End-Users, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 41: Italy, Anti-Vascular Endothelial Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 42: Italy, Anti-Vascular Endothelial Market, Segmentation By Disease, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 43: Italy, Anti-Vascular Endothelial Market, Segmentation By End-Users, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 44: Spain, Anti-Vascular Endothelial Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 45: Spain, Anti-Vascular Endothelial Market, Segmentation By Disease, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 46: Spain, Anti-Vascular Endothelial Market, Segmentation By End-Users, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 47: Eastern Europe, Anti-Vascular Endothelial Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 48: Eastern Europe, Anti-Vascular Endothelial Market, Segmentation By Disease, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 49: Eastern Europe, Anti-Vascular Endothelial Market, Segmentation By End-Users, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 50: Russia, Anti-Vascular Endothelial Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 51: Russia, Anti-Vascular Endothelial Market, Segmentation By Disease, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 52: Russia, Anti-Vascular Endothelial Market, Segmentation By End-Users, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 53: North America, Anti-Vascular Endothelial Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 54: North America, Anti-Vascular Endothelial Market, Segmentation By Disease, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 55: North America, Anti-Vascular Endothelial Market, Segmentation By End-Users, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 56: USA, Anti-Vascular Endothelial Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 57: USA, Anti-Vascular Endothelial Market, Segmentation By Disease, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 58: USA, Anti-Vascular Endothelial Market, Segmentation By End-Users, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 59: Canada, Anti-Vascular Endothelial Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 60: Canada, Anti-Vascular Endothelial Market, Segmentation By Disease, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 61: Canada, Anti-Vascular Endothelial Market, Segmentation By End-Users, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 62: South America, Anti-Vascular Endothelial Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 63: South America, Anti-Vascular Endothelial Market, Segmentation By Disease, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 64: South America, Anti-Vascular Endothelial Market, Segmentation By End-Users, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 65: Brazil, Anti-Vascular Endothelial Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 66: Brazil, Anti-Vascular Endothelial Market, Segmentation By Disease, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 67: Brazil, Anti-Vascular Endothelial Market, Segmentation By End-Users, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 68: Middle East, Anti-Vascular Endothelial Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 69: Middle East, Anti-Vascular Endothelial Market, Segmentation By Disease, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 70: Middle East, Anti-Vascular Endothelial Market, Segmentation By End-Users, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 71: Africa, Anti-Vascular Endothelial Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 72: Africa, Anti-Vascular Endothelial Market, Segmentation By Disease, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 73: Africa, Anti-Vascular Endothelial Market, Segmentation By End-Users, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 74: F. Hoffmann-La Roche AG Financial Performance
  • Table 75: Biogen Inc. Financial Performance
  • Table 76: Pfizer Inc. Financial Performance
  • Table 77: Coherus BioSciences Inc. Financial Performance
  • Table 78: Applied Molecular Genetics Inc. Financial Performance

List Of Figures

    Figure 1: Global Historic Market Growth, 2018-2023, $ Billion
  • Figure 2: Global Forecast Market Growth, 2023-2028F, 2033F, $ Billion
  • Figure 3: Global Anti-Vascular Endothelial Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 4: Global Anti-Vascular Endothelial Market, Segmentation By Disease, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 5: Global Anti-Vascular Endothelial Market, Segmentation By End-Users, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 6: Global Anti-Vascular Endothelial Market, Split By Region, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 7: Global Anti-Vascular Endothelial Market, Split By Country, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 8: Asia-Pacific, Anti-Vascular Endothelial Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 9: Asia-Pacific, Anti-Vascular Endothelial Market, Segmentation By Disease, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 10: Asia-Pacific, Anti-Vascular Endothelial Market, Segmentation By End-Users, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 11: China, Anti-Vascular Endothelial Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 12: China, Anti-Vascular Endothelial Market, Segmentation By Disease, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 13: China, Anti-Vascular Endothelial Market, Segmentation By End-Users, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 14: India, Anti-Vascular Endothelial Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 15: India, Anti-Vascular Endothelial Market, Segmentation By Disease, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 16: India, Anti-Vascular Endothelial Market, Segmentation By End-Users, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 17: Japan, Anti-Vascular Endothelial Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 18: Japan, Anti-Vascular Endothelial Market, Segmentation By Disease, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 19: Japan, Anti-Vascular Endothelial Market, Segmentation By End-Users, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 20: Australia, Anti-Vascular Endothelial Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 21: Australia, Anti-Vascular Endothelial Market, Segmentation By Disease, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 22: Australia, Anti-Vascular Endothelial Market, Segmentation By End-Users, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 23: Indonesia, Anti-Vascular Endothelial Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 24: Indonesia, Anti-Vascular Endothelial Market, Segmentation By Disease, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 25: Indonesia, Anti-Vascular Endothelial Market, Segmentation By End-Users, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 26: South Korea, Anti-Vascular Endothelial Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 27: South Korea, Anti-Vascular Endothelial Market, Segmentation By Disease, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 28: South Korea, Anti-Vascular Endothelial Market, Segmentation By End-Users, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 29: Western Europe, Anti-Vascular Endothelial Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 30: Western Europe, Anti-Vascular Endothelial Market, Segmentation By Disease, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 31: Western Europe, Anti-Vascular Endothelial Market, Segmentation By End-Users, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 32: UK, Anti-Vascular Endothelial Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 33: UK, Anti-Vascular Endothelial Market, Segmentation By Disease, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 34: UK, Anti-Vascular Endothelial Market, Segmentation By End-Users, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 35: Germany, Anti-Vascular Endothelial Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 36: Germany, Anti-Vascular Endothelial Market, Segmentation By Disease, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 37: Germany, Anti-Vascular Endothelial Market, Segmentation By End-Users, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 38: France, Anti-Vascular Endothelial Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 39: France, Anti-Vascular Endothelial Market, Segmentation By Disease, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 40: France, Anti-Vascular Endothelial Market, Segmentation By End-Users, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 41: Italy, Anti-Vascular Endothelial Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 42: Italy, Anti-Vascular Endothelial Market, Segmentation By Disease, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 43: Italy, Anti-Vascular Endothelial Market, Segmentation By End-Users, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 44: Spain, Anti-Vascular Endothelial Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 45: Spain, Anti-Vascular Endothelial Market, Segmentation By Disease, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 46: Spain, Anti-Vascular Endothelial Market, Segmentation By End-Users, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 47: Eastern Europe, Anti-Vascular Endothelial Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 48: Eastern Europe, Anti-Vascular Endothelial Market, Segmentation By Disease, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 49: Eastern Europe, Anti-Vascular Endothelial Market, Segmentation By End-Users, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 50: Russia, Anti-Vascular Endothelial Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 51: Russia, Anti-Vascular Endothelial Market, Segmentation By Disease, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 52: Russia, Anti-Vascular Endothelial Market, Segmentation By End-Users, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 53: North America, Anti-Vascular Endothelial Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 54: North America, Anti-Vascular Endothelial Market, Segmentation By Disease, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 55: North America, Anti-Vascular Endothelial Market, Segmentation By End-Users, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 56: USA, Anti-Vascular Endothelial Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 57: USA, Anti-Vascular Endothelial Market, Segmentation By Disease, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 58: USA, Anti-Vascular Endothelial Market, Segmentation By End-Users, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 59: Canada, Anti-Vascular Endothelial Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 60: Canada, Anti-Vascular Endothelial Market, Segmentation By Disease, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 61: Canada, Anti-Vascular Endothelial Market, Segmentation By End-Users, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 62: South America, Anti-Vascular Endothelial Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 63: South America, Anti-Vascular Endothelial Market, Segmentation By Disease, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 64: South America, Anti-Vascular Endothelial Market, Segmentation By End-Users, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 65: Brazil, Anti-Vascular Endothelial Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 66: Brazil, Anti-Vascular Endothelial Market, Segmentation By Disease, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 67: Brazil, Anti-Vascular Endothelial Market, Segmentation By End-Users, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 68: Middle East, Anti-Vascular Endothelial Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 69: Middle East, Anti-Vascular Endothelial Market, Segmentation By Disease, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 70: Middle East, Anti-Vascular Endothelial Market, Segmentation By End-Users, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 71: Africa, Anti-Vascular Endothelial Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 72: Africa, Anti-Vascular Endothelial Market, Segmentation By Disease, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 73: Africa, Anti-Vascular Endothelial Market, Segmentation By End-Users, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 74: F. Hoffmann-La Roche AG Financial Performance
  • Figure 75: Biogen Inc. Financial Performance
  • Figure 76: Pfizer Inc. Financial Performance
  • Figure 77: Coherus BioSciences Inc. Financial Performance
  • Figure 78: Applied Molecular Genetics Inc. Financial Performance
View Report
View Report
View Report
View Report
View Report
View Report
View Report
View Report